The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease

Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer treatment. Because of dysregulated activation of the immune system, patients with autoimmune disease (AID) are usually excluded from ICI clinical trials. Due to a large number of cancer patients with preexisting...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hui, Zhou, Jianfeng, Bai, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937882/
https://www.ncbi.nlm.nih.gov/pubmed/33692958
http://dx.doi.org/10.3389/fonc.2021.625872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937882/
https://www.ncbi.nlm.nih.gov/pubmed/33692958
http://dx.doi.org/10.3389/fonc.2021.625872

Ejemplares similares